HRAS and melanoma: Variant analysis then focused on (i) tumor suppressor genes and known melanoma hotspots; (ii) mutations known to be recurrent in the COSMIC pan-cancer database; and (iii) other oncogenic mutations, namely mutations of CBL, CTNNB1, RUNX1, SMARCA4, and TET2. More than half of the cases presented mutually exclusive activating mutations in known melanoma oncogenes such as BRAF p.G464/G466/G469/V600/K601 in 16 cases (34%), NRAS p.G12/G13/Q61 in five cases (11%), HRAS p.G12/G13 in two cases, and KIT p.L576P in two cases (Figure 2 and Table S2).